Your Article Summary
See Latest ArticlesA randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women
Psychoneuroendocrinology, 07/01/09
Tierney MC et al. - These results suggest that benefits of estrogen exposure may be limited to those with average to above average scores on the delayed verbal recall. HT dose and formulation may have contributed to these beneficial outcomes. Replication is warranted before recommendations can be made in the clinical setting.
Methods- 2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61–87, randomly assigned to receive 1 mg 17-β estradiol daily and 0.35 mg norethindrone 3 days/week or daily placebo for 2 years.
- The primary outcome was short-delay verbal recall of the California Verbal Learning Test (CVLT).
- To look for differences in response to HT by baseline short-delay recall, this study examined the primary outcome in participants grouped according to whether their baseline scores were below average for the age group or greater than or equal to this score and according to whether they met criteria for Mild Cognitive Impairment (MCI) or not.
- 133 women completed 1 year of the trial and 128 completed 2 years.
- Prespecified covariates in all repeated measures analyses of covariance (RANCOVA) included age, education, APOE 4, and prior HT use.
- RANCOVA showed no overall significant treatment effects at year 1 or year 2.
- After testing for an interaction, which was significant (p = 0.02), we found that women in the HT group who scored at or above the average showed significantly less decline than the placebo group in short-delay verbal recall after 1 year, p = 0.007 and 2 years, p = 0.01.
- No treatment effects were found in women below the average in either year.
- When grouped according to whether the participant met criteria for MCI, the interaction between treatment group and MCI subgroup was not significant.
Related Articles
Issues in postmenopausal hormone therapy: A 3-part CME newsletter series Counseling patients about bioidentical hormone preparations
Sexuality, Reproduction & Menopause, 11/13/09
Relevance Score: 72%
Issues in postmenopausal hormone therapy: depression, endometrial health, and discontinuation
Sexuality, Reproduction & Menopause, 10/09/09
Relevance Score: 71%
Bayesian Meta-analysis of Hormone Therapy and Mortality in Younger Postmenopausal Women
American Journal of Medicine, 10/27/09
Relevance Score: 70%
Hormone Therapy Can Help Some with Prostate Cancer
MedLinePlus, 11/04/09
Relevance Score: 69%
Long-term prevention with hormone-replacement therapy after the menopause: which women should be targeted?
Women's Health, 11/02/09
Relevance Score: 68%
Today in Mental Health...keeping you current
Receive free subspecialty "5-minute updates" via email
Milnacipran: Beyond a Role of Antidepressant
Clinical Neuropharmacology, 12/14/09
Atypical Depression: A Comprehensive Review
CNS Drugs, 12/14/09
Depression and Related Psychological Factors in Heart Disease
Harvard Review of Psychiatry, 12/14/09